AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05993299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study NCT04157803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acetic acid % spray
Description: If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly.
Study NCT05993299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study NCT04501406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
Study NCT04501406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
Study NCT03168828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium-Releasing Intravesical System (TAR-302-5018)
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Study NCT03264365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed
Study NCT00996463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-thermo-coagulation
Description: Electro-thermo-coagulation
Study NCT00996463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Stibogluconate
Description: Intralesional injection of sodium stibogluconate
Study NCT00996463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAC N-055
Description: Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
Study NCT03789916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90 mg bis in die
Study NCT03789916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 100 mg die
Study NCT03789916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 100 mg die
Study NCT02857608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Study NCT00483470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine AVAXIM 80U
Description: 0.5 mL, Intramuscular
Study NCT00483470 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine (HAVRIX 720)
Description: 0.5 mL, Intramuscular
Study NCT03306940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: patients were injected to the normal side with dose of 1.25 units/per site
Study NCT03306940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: patients were injected to the normal side with dose of 1.25 units/per site
Study NCT00226057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Open Label
Study NCT03083366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Description: Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Study NCT02621307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salba
Study NCT02621307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax
Study NCT02621307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM
Study NCT03009851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OBCHI
Description: Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
Study NCT01966822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, 50mg every 24 hours
Description: Dolutegravir, 50mg every 24 hours
Study NCT01966822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protease Inhibitor/ritonavir
Description: Protease Inhibitor/ritonavir
Study NCT00964392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Radiofrequency ablation
Study NCT03211169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies of bile duct stricture with pediatric biopsy forceps
Description: Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
Study NCT03211169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies of bile duct stricture with cholangioscopy-directed biopsies
Description: Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02802410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQ-Tape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
Study NCT02802410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
Study NCT02802410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Tape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
Study NCT01037218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study NCT01037218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01371981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT01773707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given as 30 minute IV infusion
Study NCT01371981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01371981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01037218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study NCT04454255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FunSpeech
Description: Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
Study NCT01371981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04152122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The dynamic stereopsis test
Description: The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
Study NCT04454255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
Study NCT04160650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer
Description: This is an educational intervention which aims to answer the questions:~1. In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~2. In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~3. In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~4. In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?
Study NCT01676207 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Angiography with collateral flow measurements
Description: * Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion.
Study NCT00720213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics BiPAP autoSV2
Description: Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
Study NCT00720213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics BiPAP autoSV2
Description: Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
Study NCT00720213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics BiPAP autoSV3
Description: Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
Study NCT00720213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics BiPAP autoSV3
Description: Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
Study NCT03617094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early percutaneous vertebroplasty (EPV)
Description: Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
Study NCT03617094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Conservative treatment (CT)
Description: Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
Study NCT01828723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF
Study NCT02475473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Chronic High-Intensity Resistance Training
Study NCT04085237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
Study NCT04085237 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Saline will be used at the same amounts as the ropivacaine arm.
Study NCT03198442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: F-18 FDG breast PET scan
Study NCT01371981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT01105897 — intervention group
Intervention type: PROCEDURE
Intervention: Endometriosis surgery
Description: Complete surgical excision of all visible endometriosis by multidisciplinary approach
Study NCT00548678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous diclofenac sodium (DIC075V)
Description: intravenous diclofenac sodium
Study NCT00548678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: intravenous ketorolac
Study NCT00548678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral diclofenac (Cataflam)
Description: oral diclofenac (Cataflam)
Study NCT00548678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: oral aspirin
Study NCT03330561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-343
Description: PRS-343
Study NCT03117153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA-5502 liquid toothpaste
Description: 6 weeks study, brush three times daily, liquid toothpaste
Study NCT03117153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same flavor solution, brush three times daily
Study NCT03733769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transmuscular quadratus lumborum block
Description: transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
Study NCT01197534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily
Study NCT01197534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: fostamatinib 100 mg twice daily/ 150 mg once daily
Study NCT01197534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, fostamatinib
Description: Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
Study NCT01197911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: single oral dose
Study NCT03289091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based continuous aerobic training
Description: Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
Study NCT03289091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based interval aerobic training
Description: Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
Study NCT02286713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Decision Aid
Description: Participants will receive study materials including a video to watch about lung cancer screening
Study NCT02286713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Educational Information
Description: Participants will receive study materials including a booklet to read about lung cancer screening.
Study NCT00595725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic Mapping
Description: Intra-Operative Lymphatic Mapping
Study NCT01707277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
Study NCT02286713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Assessments: Questionnaires
Description: Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
Study NCT02380326 — intervention group
Intervention type: PROCEDURE
Intervention: Advanced endoscopic imaging modalities
Description: Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
Study NCT01153828 — intervention group
Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription for retapamulin
Study NCT01153828 — intervention group
Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescriptions for retapamulin and topical mupirocin
Study NCT01707277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual pahramacological treatment
Study NCT01707277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual pahramacological treatment
Study NCT01153828 — intervention group
Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical fusidic acid
Description: Same day prescription for retapamulin and fusidic acid.
Study NCT02245009 — intervention group
Intervention type: PROCEDURE
Intervention: Cardioversion
Study NCT01121614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOTUS
Description: Device used to seal blood vessel
Study NCT01121614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethicon Harmonic Scalpel
Study NCT01121614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure bipolar vessel sealing device
Study NCT03412695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyFood
Description: Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
Study NCT02604095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
Study NCT03571828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 562
Description: AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
Study NCT02381847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal chemoperfusion
Description: HIPEC with cisplatin at the time of D2 radical surgery
Study NCT02422355 — intervention group
Intervention type: DEVICE
Intervention: FNS
Description: Surgical intervention using the FNS
Study NCT03982290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic, Lactobacillus plantarum PS128
Description: PS128 capsules, 2 capsules per day
Study NCT00737516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, Cord Blood
Description: Search for HLA compatible cord blood units using the NMDP registry
Study NCT00413725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef
Description: Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
Study NCT00413725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo